1-s2.0-s0040403901000715-main
TRANSCRIPT
![Page 1: 1-s2.0-S0040403901000715-main](https://reader038.vdocument.in/reader038/viewer/2022100607/577cd9fa1a28ab9e78a4918c/html5/thumbnails/1.jpg)
7/27/2019 1-s2.0-S0040403901000715-main
http://slidepdf.com/reader/full/1-s20-s0040403901000715-main 1/3
TETRAHEDRON
LETTERS
Tetrahedron Letters 42 (2001) 2019–2021Pergamon
An efficient stereoselective synthesis of
(2S ,4S ,5R)-(−
)-bulgecinine
Antoni Krasinskia and Janusz Jurczaka,b,*
aInstitute of Organic Chemistry, Polish Academy of Sciences, 01-224 Warsaw, Poland bDepartment of Chemistry, University of Warsaw, 02 -093 Warsaw, Poland
Received 29 November 2000; revised 18 December 2000; accepted 10 January 2001
Abstract— N -Benzyl-N -carbobenzyloxy-O-tert-butyldimethylsilyl-D-serinal (6) was reacted under Barbier conditions with allylbromide affording diastereoselectively (82:18) the anti -adduct 5, which was subsequently transformed into (2S ,4S ,5R)-(−)-bulgecinine (1). © 2001 Elsevier Science Ltd. All rights reserved.
a-Amino aldehydes are synthetically useful chirons,readily available from naturally occurring a-aminoacids.1 In our recent studies, involving the synthesis of antibiotic amino sugars, we have shown that suitablyprotected a-amino aldehydes are versatile chirons.2 Forexample, addition of allyltrimethylsilane to N -mono-and N ,N -diprotected a-amino aldehydes offers an easyaccess to almost enantiomerically pure both syn- andanti -adducts,3 which are readily transformed into natu-
ral products, such as 3-hydroxyproline,4 1,3-dideoxy-nojirimycin,5 statine,6 and preussin.7
Now we report a new application of our methodologyto the stereoselective synthesis of (2S ,4S ,5R)-(−)-bulge-cinine (1), an amino acid constituent of naturally occur-ring antibiotic glycopeptides called bulgecins, isolatedfrom Pseudomonas acidophila and Pseudomonasmesoacidophila.8 While bulgecins themselves show no
Scheme 1. Retrosynthetic analysis.
Keywords : asymmetric induction; amino aldehydes; allylation; epoxidation; cyclization; pyrrolidines.
* Corresponding author. Tel.: +00 48 22 632 05 78; e-mail: [email protected]
0040-4039/01/$ - see front matter © 2001 Elsevier Science Ltd. All rights reserved.
PII: S 0 0 4 0 - 4 0 3 9 ( 0 1 ) 0 0 0 7 1 - 5
![Page 2: 1-s2.0-S0040403901000715-main](https://reader038.vdocument.in/reader038/viewer/2022100607/577cd9fa1a28ab9e78a4918c/html5/thumbnails/2.jpg)
7/27/2019 1-s2.0-S0040403901000715-main
http://slidepdf.com/reader/full/1-s20-s0040403901000715-main 2/3
A. Krasinski , J . Jurczak / Tetrahedron Letters 42 (2001) 2019–20212020
biological activity, they are synergists with some b-lac-tam antibiotics found in the above-mentioned culturebroths. These properties make (−)-bulgecinine anattractive synthetic target.9
Retrosynthetic analysis, shown in Scheme 1, suggestedthat suitably protected D-serinal could serve as a start-ing material. On the basis of our earlier investigationswe assumed the use of an N ,N -diprotected derivative of D-serine.5,10 Among several possible candidates weselected N -benzyl-N -carbobenzyloxy-O-tert-butyldi-methylsilyl-D-serinal (6).11
Allyl addition to aldehyde 6, carried out under Barbierconditions at room temperature, afforded diastereose-lectively (5:7–82:18) the anti -adduct 5 in 96% yield
(Scheme 2). Olefin 5, obtained in pure form via columnchromatography, was subjected to the vanadium-catalysed epoxidation reaction,13 furnishing in 79%yield a chromatographically inseparable mixture of diastereoisomeric epoxides 8 (of syn relation betweenhydroxy and epoxy groups) and 9 (anti ) in a ratio of 76:24. Protection of the secondary hydroxy group, withacetic anhydride in pyridine, afforded a still inseparablemixture of epoxides 4 and 10 in 90% overall yield.Hydrogenation of this mixture, on palladium-on-char-coal as a catalyst, caused deprotection of the aminogroup and subsequent cyclisation to afford a mixture of diastereoisomeric pyrrolidines, which after treatmentwith benzyl chloroformate (protection of the secondaryamino group) was subjected to chromatographic sepa-ration giving two pure diastereoisomers 314 and 1115 in
Scheme 2. Reagents and conditions: (a) AllBr, Zn, satd aq. NH4Cl, THF, rt; (b) t-C4H9OOH, VO(acac)2 cat., CH2Cl2, rt; (c)
Ac2O, Py, DMAP cat., rt; (d) H2, 5% Pd/C, CH3OH, rt; (e) ClCO2CH2Ph, CH2Cl2, satd aq. NaHCO3, rt; (f) NaIO4, RuCl3 cat.,
CH3CN–CCl4 –H2O 2:2:3, 0°C; (g) 3 M aq. HCl, THF, reflux.
![Page 3: 1-s2.0-S0040403901000715-main](https://reader038.vdocument.in/reader038/viewer/2022100607/577cd9fa1a28ab9e78a4918c/html5/thumbnails/3.jpg)
7/27/2019 1-s2.0-S0040403901000715-main
http://slidepdf.com/reader/full/1-s20-s0040403901000715-main 3/3
A. Krasinski , J . Jurczak / Tetrahedron Letters 42 (2001) 2019–2021 2021
the same ratio as their precursors 8 and 9 (Scheme 2).The major diastereoisomer 3, isolated in 65% yield(calculated from the mixture of epoxides 8 and 9), wassubjected to ruthenium-catalysed oxidation16 furnishingprotected (−)-bulgecinine (2) in 80% yield. Deprotectionof both hydroxy groups by heating in a mixture of 3 Maqueous HCl with THF (2:3), followed by Pd/C hydro-genation of the benzyl carbamate, completed the syn-thesis of (2S ,4S ,5R)-(−)-bulgecinine (1) in 24% overallyield (calculated from 6) with the correct stereochem-istry. All analytical data, including [h]D −13.5 (c 0.95,H2O), are in agreement with those previouslyreported8,9 (lit. [h]D −13.1 (c 0.95, H2O)).8b
It is noteworthy that 5 undergoes the Al(Ot-C4H9)3/t-C4H9OOH epoxidation with anti -selectivity (81:19),leading to compound 9 as the major diastereoisomer.This possibility provides selective access to diastereoiso-mer 11 and, as a consequence, to 2-epi -bulgecinine.
Acknowledgements
This work was supported by the State Committee forScientific Research (Project PBZ 6.05/T09/1999).
References
1. (a) Martens, J. Topics Curr. Chem. 1984, 125 , 165; (b)
Coppola, G. M.; Schuster, H. F. Asymmetric Synthesis:
Construction of Chiral Molecules Using Amino Acids;
Wiley: New York, 1987; (c) Jurczak, J.; Gol*ebiowski, A.
Chem. Rev. 1989, 89 , 149; (d) Reetz, M. T. Chem. Rev.
1999, 99 , 1121.
2. (a) Gol*ebiowski, A.; Jurczak, J. Synlett 1993, 241; (b)
Kiciak, K.; Jacobsson, U.; Gol*ebiowski, A.; Jurczak, J.
Polish J . Chem. 1994, 68 , 199.
3. (a) Gryko, D.; Urbanczyk-Lipkowska, Z.; Jurczak, J.
Tetrahedron 1997, 53 , 13373; (b) Jurczak, J.; Prokopow-
icz, P. Tetrahedron Lett. 1998, 39 , 9835.
4. Jurczak, J.; Prokopowicz, P.; Gol*ebiowski, A. Tetra-
hedron Lett. 1993, 34 , 7107.
5. Gryko, D.; Jurczak, J. Tetrahedron Lett. 1997, 38 , 8275.
6. Veeresa, G.; Datta, A. Tetrahedron Lett. 1997, 38 , 5223.
7. (a) Veeresa, G.; Datta, A. Tetrahedron 1998, 54 , 15673;
(b) Krasinski, A.; Gruza, H.; Jurczak, J. Heterocycles, in
press.
8. (a) Imada, A.; Kintaka, K.; Nakao, M.; Shinagawa, S. J .
Antibiot. 1982, 35 , 1400; (b) Shinagawa, S.; Kashara, F.;Wada, Y.; Harada, S.; Asai, M. Tetrahedron 1984, 40 ,
3465; (c) Shinagawa, S.; Maki, M.; Kintaka, K.; Imada,
A.; Asai, M. J . Antibiot. 1985, 38 , 17.
9. (a) Wakamiya, T.; Yamanoi, K.; Nishikawa, M.; Shiba,
T. Tetrahedron Lett. 1985, 26 , 4759; (b) Bashyal, B. P.;
Chow, H.-F.; Fleet, G. W. J. Tetrahedron Lett. 1986, 27 ,
3205; (c) Ohfune, Y.; Hori, K.; Sakaitani, M. Tetrahedron
Lett. 1986, 27 , 6079; (d) Bayshal, B. P.; Chow, H.-F.;
Fleet, G. W. J. Tetrahedron 1987, 43 , 423; (e) Ohta, T.;
Hosoi, A.; Nozoe, S. Tetrahedron Lett. 1988, 29 , 329; (f)
Barrett, A. G. M.; Pilipauskas, D. J . Org . Chem. 1990,
55 , 5194; (g) Barrett, A. G. M.; Pilipauskas, D. J . Org .
Chem. 1991, 56 , 2787; (h) Hirai, Y.; Terada, T.;
Amemiya, Y.; Momose, T. Tetrahedron Lett. 1992, 33 ,
7893; (i) Oppolzer, W.; Moretti, R.; Zhou, C. Helv. Chim.
Acta 1994, 77 , 2363; (j) Madau, A.; Porzi, G.; Sandri, S.
Tetrahedron: Asymmetry 1996, 7 , 825; (k) Graziani, L.;
Porzi, G.; Sandri, S. Tetrahedron: Asymmetry 1996, 7 ,
1341; (l) Panday, S. K.; Langlois, N. Synth. Commun.
1997, 27 , 1373; (m) Maeda, M.; Okazaki, F.; Murayama,M.; Tachibana, Y.; Aoyagi, Y.; Ohta, A. Chem. Pharm.
Bull . 1997, 45 , 962; (n) Fehn, S.; Burger, K. Tetrahedron:
Asymmetry 1997, 8 , 2001.
10. Gryko, D.; Jurczak, J. Helv. Chim. Acta 2000, 83 , 2705.
11. The D-serine derivative 6 was obtained in 70% overall
yield via the following route: D-serine methyl ester hydro-
chloride was treated with 1 equiv. of benzaldehyde and 1
equiv. of triethylamine in methanol, followed by in situ
imine reduction with NaBH4, giving N -benzyl-D-serine
methyl ester. Its reaction with benzyl chloroformate
afforded N -Bn-N -Cbz-D-serine methyl ester, then the
hydroxy group was protected with TBSCl in DMF, fol-
lowed by reduction of the ester moiety with LiBH4 to
give N -Bn-N -Cbz-O-TBS-D-serinol. Finally, oxidation of
this amino alcohol using the TEMPO procedure12
afforded the desired aldehyde 6.
12. (a) Leanna, M. R.; Sowin, T. J.; Morton, H. E. Tetra-
hedron Lett. 1992, 33 , 5029; (b) Jurczak, J.; Gryko, D.;
Kobrzycka, E.; Gruza, H.; Prokopowicz, P. Tetrahedron
1998, 54 , 6051.
13. Mihelich, E. D.; Daniels, K.; Eickhoff, D. J. J . Am.
Chem. Soc. 1981, 103 , 7690.
14. Selected data: mp 64–66°C (AcOEt/hexane); [h ]D −38.6 (c
1.0, CHCl3); ESIMS HR calcd for (M+Na)+
(C22H35NO6NaSi) 460.2126, found 460.2106; 1H NMR
(500 MHz, DMSO-d 6): 7.37–7.27 (m, 5H), 5.12 (d, J =
12.3 Hz, 0.5H), 5.11–5.01 (m, 2H), 4.96 (d, J =12.3 Hz,0.5H), 4.73 (dt, J 1=J 2=6.0 Hz, J 3=12.0 Hz, 1H), 3.89–
3.84 (m, 0.5H), 3.83–3.69 (m, 2.5H), 3.68–3.62 (m, 0.5H),
3.58–3.53 (m, 0.5H), 3.22–3.13 (m, 1H), 2.28–2.20 (m,
1H), 2.11–2.00 (m, 1H), 1.98 (s, 3H), 0.81 (s, 4.5H), 0.78
(s, 4.5H), −0.01 to −0.13 (m, 6H); 13C NMR (125 MHz,
DMSO-d 6): 170.23, 170.18, 153.94, 153.93, 137.18,
136.86, 128.88, 128.85, 128.54, 128.49, 128.32, 128.14,
77.03, 76.36, 66.69, 66.47, 66.31, 65.64, 62.39, 62.06,
61.57, 60.62, 60.12, 59.47, 32.60, 31.72, 26.09, 26.06,
21.46, 18.21, 18.17, −5.17, −5.28, −5.30.
15. Selected data: [h ]D −9.32 (c 1.0, CHCl3); ESIMS HR
calcd for (M+Na)+ (C22H35NO6NaSi) 460.2126, found
460.2157;1
H NMR (500 MHz, DMSO-d 6): 7.37–7.27 (m,5H), 5.16–4.99 (m, 3H), 4.71 (t, J =4.6 Hz, 1H), 3.90–
3.76 (m, 2H), 3.68–3.60 (m, 1H), 3.54–3.38 (m, 3H),
2.29–2.13 (m, 1H), 1.99–1.93 (m, 1H), 1.97 (s, 3H),
0.86–0.77 (m, 9H), 0.04 to −0.10 (m, 6H); 13C NMR (125
MHz, DMSO-d 6): 169.63, 154.41, 154.22, 136.60, 128.33,
127.80, 127.46, 74.34, 73.76, 66.11, 65.49, 65.17, 62.06,
61.72, 61.50, 60.88, 58.57, 57.90, 33.01, 32.04, 25.63,
20.83, 17.80, −5.63.
16. Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless,
K. B. J . Org . Chem. 1981, 46 , 3936.
.
.